Tim Watts, CFO at Shield Therapeutics #STX presenting at our Life Sciences Investor Briefing Watch Now

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price: 1,671.60
Bid: 1,659.20
Ask: 1,660.20
Change: 13.80 (0.83%)
Spread: 1.00 (0.06%)
Open: 1,649.20
High: 1,678.20
Low: 1,646.40
Yest. Close: 1,657.80
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

WINNERS & LOSERS SUMMARY: Plus500 Up On Share Buyback, New Customers

Tue, 13th Aug 2019 10:09

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.


TUI, up 3.5%. The Anglo-German travel company reported revenue growth on strong performances by its experiences businesses in the third quarter. For the three months ended June, revenue rose 3.7% to EUR4.75 billion from EUR4.58 billion the year before. Revenue was supported by strong performances by the Destination Experiences, Holiday Experiences, and Cruises divisions. This was offset by weakness in the Western Region, Northern Region, and All Other Segments units. However, underlying earnings before interest, taxes & amortisation narrowed 46% to EUR100.9 million from EUR186.8 million a year prior. Profit performance was hurt by the Markets & Airlines unit sinking to a EUR103.9 million underlying Ebita loss from a EUR37.2 million profit the year prior. TUI reiterated its full-year guidance for underlying Ebita to fall by up to 26% from last year. "TUI had the kitchen-sink experience earlier in the year with two profit warnings, so the fact that there are no further shocks has resulted in a warm share price reaction to these numbers," said Interactive Investor's Richard Hunter.

GlaxoSmithKline, up 0.5%. JPMorgan restarted coverage on the drugmaker with a Neutral rating.


Rolls-Royce Holdings, down 2.7%. Moody's Investors Service downgraded the credit rating for the jet engine maker citing weak cash flow and high leverage levels. The credit ratings agency downgraded the long-term debt rating for the FTSE 100-listed firm to Baa1 from A3 previously. The outlook was boosted to Stable from Negative. Moody's downgraded the rating for Rolls-Royce amid adjusted leverage levels sitting at 5.3 times earnings, with the credit analyst not expecting this to fall below 4.0 times over the next year to year-and-a-half. The high cost of rectifying issues with the cracking blades of the Trent 1000 aircraft engines, as well as "limited" free cash flow also worried Moody's.

Croda International, down 2.2%. Goldman Sachs cut the speciality chemicals company to Sell from Neutral.


Plus500, up 19%. The spread betting and contract-for-difference said it has "performed well", despite reporting a steep drop in both revenue and profitability and also slashing its dividend. Plus500's revenue for the six months to June fell 68% year-on-year to USD148.0 million, with pretax profit slumping 82% to USD63.9 million. Plus500's net profit fell 80% to USD51.6 million, with earnings before interest, taxes, depreciation, and amortisation down 81% to USD65.6 million. Plus500 will be returning USD0.2734 per share to shareholders for the period, an 80% reduction from the USD1.3786 paid out a year before. However, the firm has also announced a share buyback worth USD50.0 million. The company said the performance was in line with expectations, with the second quarter improving on the first after financial markets volatility increased. Second quarter new customer numbers were 23% ahead of the first quarter, with active customer numbers rising 11%.


Aston Martin Lagonda, down 4.0%. Credit Suisse downgraded the Valkyrie hypercar maker to Neutral from Outperform.


Oilex, up 60%. The oil and gas company announced its request for a halt in the trading of its shares on the Australian Stock Exchange was granted with immediate effect. Oilex said its suspension on the ASX is in relation to a proposed acquisition, and will be in place until Thursday, when it makes an announcement relating to the acquisition. Trading in Oilex's shares on London's AIM however will continue during the period. On Wednesday last week, Oilex agreed to acquire Holloman Energy Corp's 48% interest in the PEL 112 and PEL 444 licences within the Cooper-Eromanga basins, onshore Australia for AUD145,500 in cash and shares.


John Menzies, down 4.5%. The aviation services firm blamed the grounding of Boeing Co's 737 MAX and weak cargo volumes for an interim loss. John Menzies's pretax loss for the six months to June was GBP4.4 million, after a GBP8.3 million profit the year before. On an underlying basis, pretax profit was down 47% to GBP8.2 million. The company did manage to increase revenue, by 3.6% to GBP649.9 million and has kept the interim payout flat at 6.0 pence a share. John Menzies said the aviation sector has seen a decline in airline flight schedules and reduced cargo volumes, while the company has also been hurt by contract losses in the Dominican Republic and Panama. The firm is now looking to deliver over GBP10 million of cost savings, most of which will be realised in 2020, with "decisive" action now taken to "right size" the business.

More News

BROKER RATINGS SUMMARY: Morgan Stanley Raises SSE To Overweight

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:----------FTSE 100----------DEUTSCHE BANK RAISES RENTOKIL INITIAL

10 Sep 19 09:32

Aurora Investment Trust Net Assets Rise But Total Interim Return Lags

(Alliance News) - Aurora Investment Trust PLC on Monday said its net asset value rose in the first six months of the year but total return lagged behind its benchmark index.At June 30, a of

9 Sep 19 12:12

BROKER RATINGS SUMMARY: Deutsche Bank Raises BHP And Cuts Antofagasta

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:----------FTSE 100----------DEUTSCHE BANK RAISES BHP

4 Sep 19 09:32

Tuesday broker round-up

(Sharecast News) - easyJet: Kepler Cheuvreux downgrades to reduce with a target price of 820p.

3 Sep 19 12:59

BROKER RATINGS SUMMARY: Deutsche Bank Starts Taylor Wimpey At Buy

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:----------FTSE 100----------DEUTSCHE BANK INITIATES TAYLOR WIMPEY

3 Sep 19 09:40

LONDON MARKET OPEN: Ferguson-Wolseley Rises; Pound Falls Below USD1.20

(Alliance News) - Stock prices in London opened mixed on Tuesday, with Ferguson the best blue-chip performer after the company decided to split its UK and US operations, while the pound fell below

3 Sep 19 08:49

Monday broker round-up

(Sharecast News) - Beazley: UBS upgrades to buy with a target price of 650p.

2 Sep 19 13:16

Former Glaxo Vice President To Lead C4X Discovery Advisory Network

(Alliance News) - C4X Discovery Holdings PLC on Monday said it is forming a drug discovery advisory network chaired by "renowned industry veteran" Robin Carr.Shares in C4X were up

2 Sep 19 12:02

BROKER RATINGS SUMMARY: Goldman Sachs Says Buy Unilever, Sell M&S

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday afternoon:----------FTSE 100----------GOLDMAN SACHS WITH

2 Sep 19 09:41

BROKER RATINGS SUMMARY: UBS Raises Greggs; Peel Hunt Lifts Chesnara

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday afternoon and Wednesday morning:----------FTSE 100----------KEPLER RAISES

28 Aug 19 09:37

GlaxoSmithKline's Dreamm-2 Multiple Myeloma Trial Results Encouraging

(Alliance News) - GlaxoSmithKline PLC on Friday reported positive headline results from its Dreamm-2 study of belantamab mafodotin in multiple myeloma.The study, which involved 196 patients

23 Aug 19 07:46

GlaxoSmithKline reveals positive results from belantamab mafodotin trial

(Sharecast News) - GlaxoSmithKline announced positive headline results from the pivotal 'DREAMM-2' open-label, randomised study of two doses of belantamab mafodotin on Friday.

23 Aug 19 07:29

Glaxo's ViiV Reports Positive Study Results Of HIV-Treatment Regimen

(Alliance News) - GlaxoSmithKline PLC on Thursday said ViiV Healthcare reported positive headline results from its global phase III ATLAS-2M study.ViiV Healthcare is a specialist HIV owned

22 Aug 19 08:20

GlaxoSmithKline upbeat on latest test results from ViiV Healthcare

(Sharecast News) - GlaxoSmithKline reported on Thursday that its specialist HIV company ViiV Healthcare had announced positive headline results from its phase 3 'ATLAS-2M' study of the investigational, long-acting, injectable, two-drug regimen (2DR) of its cabotegravir and Janssen's rilpivirine for the treatment of HIV.

22 Aug 19 07:29

Glaxo Submits Japanese Application For Daprodustat Anaemia Drug

(Alliance News) - GlaxoSmithKline PLC on Wednesday said it has submitted a new drug application in Japan for anaemia drug daprodustat.The application was submitted to the Japanese Ministry

21 Aug 19 08:38

Login to your account

Don't have an account? Click here to register.